New phase 3b findings showed adults with type 2 diabetes treated with Novo Nordisk’s Xultopha, demonstrated statistically significant reduction in HbA1c, change in body weight and a lower rate of hypoglycemia compared with patients treated with insulin glargine.

Findings from the phase 3b DUAL(TM) V 26-week trial that compared the efficacy and safety of Xultophy® versus insulin glargine, both added on to metformin, in patients with type 2 diabetes uncontrolled on insulin glargine (20-50 units/day), were presented at at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, MA, U.S.

Source: Novo Nordisk